Genmab — September 2013
-
aabo skulle skære pænt i potentialet på arzerra for at kunne forsvare 145
-
mener han indregner at de fejler i fase 3 her til december
-
det kan man sagtens. Og det er bestemt en mulighed at den ikke når primary endpoint, hvorfor man så ikke regner med godkendelse, hvilket Aabo så heller ikke gør
-
i gamle dage (før 08) sagde vi at fase 3 var 75% sandsynlighed. Jeg kan huske at jeg har set noget primary endpoint statiistik. Og det er ikke 75% der nå det. Men når man er kommet så langt i kræft så er det mere end 50% vil jeg tro.
-
-
ofatumumab in combination with bendamustine
is an effective and tolerable therapy, providing high response rates
and an acceptable safety profile for patients with either previously
untreated CLL who are inappropriate for fludarabine-based therapy,
or patients with relapsed CLL -
hvor kommer den poster fra?
-
jeg synes cr er rigtigt stærke
-
-
tak
-
Dobbelt op på CR ifht Rituximab http://www.ncbi.nlm.nih.gov/pubmed/22869884
-
er det ikke de data Jan sagde at GEN ville præsentere på iwcll i Køln? Det ser dælme godt ud!
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind